Rewalk Robotics Stock Earnings Reports

Lifeward completed an equity-based acquisition of Oratech, gaining a protein oral delivery platform (including ORMD-0801 oral insulin) while keeping Oramed responsible for its clinical program and funding — providing Lifeward optional upside with limited near-term operating burden. The company is focused on scaling its core neurorehabilitation MedTech business (notably ReWalk) and pursuing complementary strategic acquisitions (including an upper-body exoskeleton for stroke survivors). Q1 revenue was $3.9M versus $5.0M a year ago, primarily hurt by timing-related lower AlterG shipments tied to working capital constraints and a manufacturing transition (facility moves and contract manufacturing). ReWalk personal exoskeleton revenue grew 11% year-over-year to $1.6M, with strong international and reimbursement progress (Medicare Advantage coverage from Aetna, Humana and UnitedHealthcare). Gross margin declined to 34.2% from 42.2%, largely due to FX movements, tariffs and lower production absorption. GAAP operating loss widened due to a one-time ~$4.9M noncash R&D expense tied to the Oratech IP acquisition; on a non-GAAP basis, adjusted operating expenses fell 12% to $5.9M and adjusted operating loss was flat year-over-year at $4.6M. Cash improved materially to $11.4M (from $2.2M year-end 2025) following a $10M convertible note financing and ~ $6.5M of cash from the Oratech transaction. Management expects to work through the AlterG backlog across Q2–Q3, hold full-year revenue roughly in line with 2025, and exit the year on an improved trajectory toward profitability while continuing disciplined cash management and channel-focused commercial expansion.